Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Endo Pharmaceuticals |
---|---|
Information provided by: | Endo Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT00263575 |
The purpose of this study is to evaluate the long-term safety of sublingual fentanyl tablets in cancer patients who are experiencing breakthrough pain.
Condition | Intervention | Phase |
---|---|---|
Pain Cancer |
Drug: EN3267 |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety Study |
Official Title: | A Multiple-Dose, Non-Randomized, Open-Label, Multicenter Study to Evaluate the Long-Term Safety and Effectiveness of EN3267 in the Treatment of Breakthrough Pain in Cancer Patients |
Ages Eligible for Study: | 17 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | EN3267-007 |
Study First Received: | December 7, 2005 |
Last Updated: | September 12, 2007 |
ClinicalTrials.gov Identifier: | NCT00263575 |
Health Authority: | United States: Food and Drug Administration |
EN3267 Breakthrough Pain Safety Study Fentanyl Tablets |
Fentanyl Pain |